/GERD Drugs and Devices Market Forecast, Sales Revenue, Comprehensive Research Study, Demand, Growth, Segmentation and Key Companies
GERD Drugs and Devices Market Forecast, Sales Revenue, Comprehensive Research Study, Demand, Growth, Segmentation and Key Companies
emergenMay 23, 2021
The global GERD Drugs and Devices market is forecasted to be worth USD 6.14 Billion by 2027, according to a current analysis by Emergen Research. In November 2020, Sandoz Inc. announced it had shipped pantoprazole sodium to supply the hospitals for injection, 40 mg to Civica Rx. It is a part of a multiyear collaboration for the reduction in supply shortages with several other pipeline medicines.
The new research report titled ‘Global GERD Drugs and Devices Market’, published by Emergen Research, proffers a comprehensive study of the GERD Drugs and Devices industry, while estimating the overall market size and the size and share of the key regional segments of the global market over historical per
Impacto potencial de la candidata a vacuna contra el dengue de Takeda, reforzado por los resultados de seguridad a largo plazo y eficacia
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Japan s Dengue Vaccine Candidate Demonstrated Long-Term Safety and Efficacy
precisionvaccinations.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from precisionvaccinations.com Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical Company Limited
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treat
Saturday, May 22, 2021 10:31AM IST (5:01AM GMT)
Osaka, Japan:
− If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in Those That Are Refractory, With or Without Resistance (R/R)
− NDA based on Phase 3 Trial of Maribavir Which Met Its Primary Endpoint of Superiority Compared to Conventional Antiviral Therapies in Transplant Recipients with R/R CMV Infection
1
− The U.S. Food & Drug Administration Granted Maribavir Breakthrough Therapy Designation as a Treatment for CMV Infection in Transplant Patients Resistant or Refractory to Prior Therapy